#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4600	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2481	544.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1491	1491	C	667	C	557	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7104	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4121	516.4	0	.	n	.	0	T695C	SNP	695	695	T	1302	1302	C	526	C,A,T	430,4,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7104	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4121	516.4	0	.	n	.	0	G1337A	SNP	1337	1337	G	1944	1944	A	632	A,G	550,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7104	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4121	516.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2578	2578	C	652	C,T,A	548,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7104	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4121	516.4	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3204	3204	T	566	T,A,G	504,1,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	7104	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4121	516.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2652	2652	A	655	A,C	570,2	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	730	folP	852	852	100.0	folP.l6.c4.ctg.1	1932	113.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1232	1234	AGC	148;148;148	A;G;C	122;130;125	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1702	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3707	137.2	1	SNP	p	S91F	0	.	.	271	273	TCC	718	720	TCC	141;140;142	T;C;C	119;121;117	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1702	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3707	137.2	1	SNP	p	D95G	0	.	.	283	285	GAC	730	732	GAC	139;136;137	G,T;A,G;C	115,1;118,1;121	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1702	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3707	137.2	1	SNP	p	D95N	0	.	.	283	285	GAC	730	732	GAC	139;136;137	G,T;A,G;C	115,1;118,1;121	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	662	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1717	115.4	0	.	p	.	0	A39T	NONSYN	115	117	GCC	676	678	ACC	187;187;187	A,G;C,A;C	158,1;157,1;158	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	662	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1717	115.4	0	.	p	.	0	R44H	NONSYN	130	132	CGC	691	693	CAC	185;185;185	C;A,G;C	156;158,1;159	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	662	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1717	115.4	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	874	876	CAC	185;183;183	C,T,A;A;C	155,1,1;162;158	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	662	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1717	115.4	1	SNP	p	G45D	0	.	.	133	135	GGC	694	696	GGC	186;186;186	G;G;C	160;158;161	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	452	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1413	95.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1490	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3429	130.1	1	SNP	p	D86N	0	.	.	256	258	GAC	870	872	GAC	169;169;169	G;A;C	139;134;139	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1490	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3429	130.1	1	SNP	p	S87R	0	.	.	259	261	AGT	873	875	AGT	169;170;170	A;G;T	137;139;139	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1490	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3429	130.1	1	SNP	p	S87I	0	.	.	259	261	AGT	873	875	AGT	169;170;170	A;G;T	137;139;139	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1490	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3429	130.1	1	SNP	p	S87W	0	.	.	259	261	AGT	873	875	AGT	169;170;170	A;G;T	137;139;139	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	1490	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3429	130.1	1	SNP	p	S88P	0	.	.	262	264	TCC	876	878	TCC	168;168;167	T;C,T;C	141;138,1;141	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1392	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3177	131.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1811	1813	GGC	165;165;163	G;G;C	144;137;138	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	1100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2896	113.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1493	1495	GCA	177;178;178	G;C,T;A	152;148,1;148	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2896	113.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1496	1498	ATC	178;179;181	A;T,A;C	146;145,1;152	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2896	113.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1508	1510	GTG	182;182;183	G;T,G;G	150;148,1;147	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2896	113.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1508	1510	GTG	182;182;183	G;T,G;G	150;148,1;147	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2896	113.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2012	2014	ACC	136;137;137	A;C;C	121;116;115	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2896	113.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2066	2068	GCG	135;133;133	G;C;G,C	121;106;108,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2896	113.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2066	2068	GCG	135;133;133	G;C;G,C	121;106;108,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2896	113.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2189	2191	GGC	144;145;145	G,C;G;C,T	125,1;127;127,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2896	113.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2198	2200	GGC	144;145;143	G;G;C	122;122;125	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	1100	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2896	113.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2216	2218	CCG	137;138;138	C;C;G,C	115;122;116,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1566	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3429	136.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	888	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2209	120.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	742	742	C	138	C	123	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1403	17.5	0	.	p	.	0	H217N	NONSYN	649	651	CAT	1257	1259	AAT	5;5;5	A;A;T	5;5;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1403	17.5	0	.	p	.	0	D218N	NONSYN	652	654	GAT	1260	1262	AAT	5;5;5	A;A;T	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1403	17.5	0	.	p	.	0	A222V	NONSYN	664	666	GCT	1272	1274	GTT	5;5;5	G;T;T	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1403	17.5	0	.	p	.	0	V226A	NONSYN	676	678	GTA	1284	1286	GCA	5;5;5	G;C;A	5;5;5	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1403	17.5	0	.	p	.	0	.	MULTIPLE	700	702	ACT	1307	1309	GTA	4;4;4	G;T;A	4;4;4	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	82	porB1a	984	171	90.29	porB1a.l15.c4.ctg.1	1403	17.5	0	.	p	.	0	D238fs	FSHIFT	712	712	G	1319	1319	G	3	G	3	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	886	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1807	144.1	0	.	p	.	0	E48G	NONSYN	142	144	GAA	553	555	GGA	194;194;195	G;G;A	161;157;160	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	886	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1807	144.1	0	.	p	.	0	G50N	NONSYN	148	150	GGC	559	561	AAC	191;192;191	A;A;C	158;159;158	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	886	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1807	144.1	0	.	p	.	0	F135L	NONSYN	403	405	TTT	814	816	CTT	163;163;163	C;T;T,G	144;134;137,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	886	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1807	144.1	0	.	p	.	0	R143G	NONSYN	427	429	AGA	838	840	GGA	161;161;161	G,C;G;A,C	137,1;135;134,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	886	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1807	144.1	0	.	p	.	0	D171G	NONSYN	511	513	GAT	922	924	GGT	162;163;163	G;G,A;T	137;135,1;137	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	886	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1807	144.1	0	.	p	.	0	G189S	NONSYN	565	567	GGC	976	978	AGC	166;167;169	A;G;C	141;142;141	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	886	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1807	144.1	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1042	1042	T	177	T	145	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	886	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1807	144.1	1	SNP	p	G120K	0	.	.	358	360	GGT	769	771	GGT	176;176;176	G;G,A;T	151;152,1;149	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	886	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1807	144.1	1	SNP	p	A121N	0	.	.	361	363	GCC	772	774	GCC	174;174;174	G;C;C	145;144;144	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	886	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1807	144.1	1	SNP	p	A121D	0	.	.	361	363	GCC	772	774	GCC	174;174;174	G;C;C	145;144;144	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2972	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	5256	169.4	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2235	2237	AAT	169;172;172	A;A;T	149;147;150	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	486	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1343	108.0	1	SNP	p	V57M	1	.	.	169	171	ATG	667	669	ATG	174;173;172	A;T;G	155;155;159	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
